Comparative Effectiveness of Therapies for Children With Autism Spectrum Disorders
Key Questions 3–7
KQ 3: Are there any identifiable changes early in the treatment phase that predict treatment outcomes?
KQ 4: What is the evidence that effects measured at the end of the treatment phase predict long-term functional outcomes?
KQ 5: What is the evidence that specific intervention effects measured in the treatment context generalize to other contexts (e.g., people, places, materials)?
KQ 6: What evidence supports specific components of treatment as driving outcomes, either within a single treatment or across treatments?
KQ 7: What evidence supports the use of a specific treatment approach in children under the age of 2 years who are at high risk of developing autism based upon behavioral, medical, or genetic risk factors?
- Warren Z, Veenstra V-W, Stone W, et al. Therapies for Children With Autism Spectrum Disorders. Comparative Effectiveness Review No. 26 (Prepared by the Vanderbilt University Evidence-based Practice Center under Contract No. 290-2007-10065-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2011. AHRQ Publication No. 11-EHC029-EF.
Your slide tray is being processed.